Towards a therapeutic breast cancer vaccine: The next steps

Expert Review of Vaccines

Volumn 4, Issue 6, 2005, Pages 831-841

  Emens, Leisha A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Cancer vaccines; Combinatorial immunotherapy; Immune modulation; Immune tolerance

Indexed keywords

BEVACIZUMAB; BREAST CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUCOCORTICOID TUMOR NECROSIS FACTOR RECEPTOR; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; KEYHOLE LIMPET HEMOCYANIN; MUCIN 1; PACLITAXEL; TOLL LIKE RECEPTOR; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR VACCINE; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CANCER VACCINE; MONOCLONAL ANTIBODY;

ANTIBODY TITER; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; COLITIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DERMATITIS; DNA DAMAGE; DRUG MECHANISM; ENTEROCOLITIS; HELPER CELL; HEPATITIS; HUMAN; HUMORAL IMMUNITY; HYPOPHYSITIS; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; INJECTION SITE REACTION; MAJOR HISTOCOMPATIBILITY COMPLEX; NATURAL KILLER T CELL; ONCOGENE NEU; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; UVEITIS; ANIMAL; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG SCREENING; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CANCER VACCINES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; PACLITAXEL; RANDOMIZED CONTROLLED TRIALS; T-LYMPHOCYTES;

EID: 29944440750     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.6.831     Document Type: Review

References (118)

1. American Cancer Society. American Cancer Society: Breast Cancer Facts and Figures 2001-2002. American Cancer Society, Atlanta, GA, USA (2002).
2. Slamon D, Clark G, Wong S et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
3. Slamon D, Godolphin W, Jones L et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712 (1989).
4. Sorlie T, Perou C, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. 98, 10869-10874 (2001). Important report characterizing the clinical heterogeneity of breast cancers at the genetic level.
5. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. 100, 8418-8423 (2003).
6. Emens L, Davidson N. Trastuzumab in breast cancer. Oncology 18, 1117-1128 (2004). Comprehensive review of the clinical utility of trastuzumab in metastatic breast cancer.
7. Hampton T. Monoclonal antibody therapies shine in breast cancer clinical trials. JAMA 293, 2985-2989 (2005).
8. Arteaga C. Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing breast cancer. Breast Cancer Res. 5, 96-100 (2003).
9. Pietras R, Poen J, Gallardo D et al. Monoclonal antilbody to HER-2/neu receptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. Cancer Res. 59, 1347-1355 (1999).
10. Mayfield S, Vaughn J, Kute T. DNA strand breaks and cell cycle perturbation in Herceptin treated breast cancer cell lines. Breast Cancer Res. Treat. 70, 123-129 (2001).
11. Lee S, Yang W, Lan K et al. Enhanced sensitization to taxol-induced apoptosis by Herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Res. 62, 5703-5710 (2002).
12. Mohsin S, Weiss H, Gutierrez M et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin. Oncol. 10, 2460-2468 (2005).
13. Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain R. Herceptin acts as an antiangiogenic cocktail. Nature 416, 279-280 (2002).
14. Clynes R, Towers T, Presta L, Ravetch J. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 6, 443-446 (2000).
15. Gennari R, Menard S, Fagnoni F et al. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res. 10, 5650-5655 (2004).
16. Kono K, Sato E, Naganuma H et al. Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T-lymphocytes. Clin. Cancer Res. 10, 2538-2544 (2004).
17. zum Buschenfelde C, Hermann C, Schmidt B, Peschel C, Bernhard H. Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of Class I-restricted HER2-specific T-lymphocytes against HER2-overexpressing tumor cells. Cancer Res. 62, 2244-2247 (2002).
18. Riker A, Cormier J, Panelli M et al. Immune selection after antigen-specific immunotherapy of melanoma. Surgery 126, 112-120 (1999).
19. Davis T, Czerwinski D, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin. Cancer Res. 5, 611-615 (1999).
20. Knutson K, Almand B, Dang Y, Disis M. Neu antigen-variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res. 64, 1146-1151 (2004).
21. Walker L, Abbas A. The enemy within: keeping self-reactive T-cells at bay in the periphery. Nature Rev. Immunol. 21, 11-19 (2001).
22. Morgan D, Kreuwel H, Fleck S et al. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 160, 643-651 (1998).
23. Lui G, Fairchild P, Smith R et al. Low avidity antigen recognition of self antigen by T-cells permits escape from central tolerance. Immunity 3, 407-415 (1995).
24. + T-cell tolerance and cancer immunotherapy. J. Immunother. 26, 1-11 (2003).
25. + T-cells in tumor-bearing mice. J. Immunol. 174, 2563-2572 (2005).
26. Hernandez J, Ko A, Sherman L. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J. Immunol. 166, 3908-3914 (2001).
27. Gross D, Graff-Dubois S, Opolon P et al. High vaccination efficiency of low affinity epitopes in antitumor immunotherapy. J. Clin. Invest. 113, 425-433 (2004).
28. + T-cells to the antitumor immune response. J. Exp. Med. 201, 1591-1602 (2005). Demonstrates the ability of cyclophosphamide to abrogate regulatory T-cells and facilitate the development of high-avidity antigen-specific effector T-cells by vaccination.
29. O'Garra A, Vierira P. Regulatory T-cells and mechanisms of immune system control. Nature Med. 10, 801-805 (2004). Detailed review of regulatory T-cells.
30. Serafini P, De Santo C, Marigo I et al. Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53, 64-72 (2004).
31. Greenwald R, Freeman G, Sharpe A. The B7 family revisited. Ann. Rev. Immunol. 23, 515-548 (2005).
32. Watts T. TNF/TNFR family members in costimulation of T-cell responses. Ann. Rev. Immunol. 23, 23-68 (2005).
33. Caras I, Grigorescu A, Stavaru K et al. Evidence for immune defects in breast and lung cancer patients. Cancer Immunol. Immunother. 53, 1146-1152 (2004).
34. Molling J, Kolgen W, van der Vliet H et al. Peripheral blood IFN-γ-secreting Vα24 Vβ1 NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int. J. Cancer 116, 87-93 (2005).
35. Wolf A, Wolf D, Steurer M et al. Increase of regulatory T-cells in the peripheral blood of cancer patients. Clin. Cancer Res. 9, 606-612 (2003).
36. Treilleux I, Blay J, Bendriss-Vermare N et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin. Cancer Res. 10, 7466-7474 (2004).
37. Pockaj B, Basu G, Pathangey L et al. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann. Surg. Oncol. 11, 328-339 (2004).
38. Gobbi G, Mirandola P, Micheloni C et al. Expression of HLA class I antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast carcinoma lesions. Int. J. Oncol. 25, 1625-1629 (2004).
39. Hermann F, Lehr H, Drexler I et al. HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res. 64, 215-220 (2004).
40. Polat M, Taysi S, Polat S, Boyuk A, Bakan E. Elevated serum arginase activity levels in patients with breast cancer. Surgery Today 33, 655-661 (2003).
41. + T-cells. J. Immunol. 175, 1483-1490 (2005).
42. Wingett D, Vestal R, Forcier K, Hadjokas N, Nielson C. CD40 is functionally expressed on human breast carcinomas: variable inducibility by cytokines and enhancement of Fas-mediated apoptosis. Breast Cancer Res. Treat. 50, 27-36 (1998).
43. Tringler B, Zhuo S, Pilkington G et al. B7-H4 is highly expressed in ductal and lobular breast cancer. Clin. Cancer Res. 11, 1842-1848 (2005).
44. Salceda S, Tang T, Kmet M et al. The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation. Exp. Cell Res. 306, 128-141 (2005).
45. Emens L, Jaffee E. Towards a breast cancer vaccine: work in progress. Oncology 17, 1200-1211 (2003). Comprehensive review of clinical trials testing breast cancer vaccines.
46. Disis M, Calenoff E, McLaughlin G et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res. 54, 16-20 (1994).
47. Disis M, Pupa S, Gralow J et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J. Clin. Oncol. 15, 3363-3367 (1997).
48. Miles D, Papazisi K. Rationale for the clinical development of STn-KLH (Theratope®) and antiMUC-1 vaccines in breast cancer. Clin. Breast Cancer 3(Suppl. 4), S134-S138 (2003).
49. + T-cell responses in antitumor immunity. Curr. Opin. Immunol. 10, 588-594 (1998).
50. Curcio C, Di Carlo E, Clynes R et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established HER-2/neu carcinomas. J. Clin. Invest. 111, 1116-1118 (2003).
51. Spadaro M, Ambrosino E, Iezzi M et al. Cure of mammary carcinomas in HER-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin. Cancer Res. 11, 1941-1952 (2005).
52. Disis M, Grabstein K, Sleath P, Cheever M. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5, 1289-1297 (1999).
53. Disis M, Schiffman K, Gooley T et al. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 6, 1347-1350 (2000).
54. Disis M, Gooley T, Rinn K et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J. Clin. Oncol. 20, 2624-2632 (2002).
55. Knutson K, Schiffman K, Cheever M, Disis M. Immunization of cancer patients with a HER-2/neu HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin. Cancer Res. 8, 1014-1018 (2002).
56. Knutson K, Schiffman K, Disis M. Immunisation with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J. Clin. Invest. 107, 477-484 (2001).
57. Salazar L, Fikes J, Southwood S et al. Immunisation of cancer patients with HER-2/neu-derived peptides demonstrating high affinity binding to multiple class II alleles. Clin. Cancer Res. 9, 5559-5565 (2003).
58. Disis M, Goodell V, Schiffman K, Knutson K. Humoral epitope-spreading following immunization with a HER-27/neu peptide based vaccine in cancer patients. J. Clin. Immunol. 24, 571-578 (2004).
59. Murray J, Gillogly M, Przepiorka D et al. Toxicity, immunogenicity and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte-macrophage colony stimulating factor in HLA-A2* patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 8, 3407-3418 (2002).
60. Disis M, Schiffman K, Guthrie K et al. Effect of dose on immune response in patients vaccinated with a HER-2/neu intracellular domain protein-based vaccine. J. Clin. Oncol. 22, 1916-1925 (2004).
61. Morse M, Clay T, Collin K et al. HER2 dendritic cell vaccines. Clin. Breast Cancer 3(Suppl. 4), S164-S172 (2003).
62. Carr A, Rodriguez E, del Carmen Arango M et al. Immunotherapy of advanced breast cancer with a heterophilic ganglioside (NeuGcGM3) cancer vaccine. J. Clin. Oncol. 21, 1015-1021 (2003).
63. Gilewski T, Adluri S, Ragupathi G et al. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6, 1693-1701 (2000).
64. Gilewski T, Ragupathi G, Bhuta S et al. Immunization of metastatic breast cancer patients with a fully synthetic Globo H conjugate: a Phase I trial. Proc. Natl. Acad. Sci. 98, 3270-3275 (2001).
65. Adluri S, Gilewski T, Zhang S et al. Specificity analysis of sera from breast cancer patients vaccinated with MUC1-KLH plus QS-21. Br. J. Cancer 79, 1806-1812 (1999).
66. Snijdewint F, von Mensdorff-Pouilly S, Karuntu-Wanamarta A et al. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int. J. Cancer 93, 97-106 (2001).
67. Muselli C, Ragupathi G, Gilewski T et al. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1. Int. J. Cancer 97, 660-667 (2002).
68. Miles D, Towlson K, Graham R et al. A randomized Phase II study of Sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br. J. Cancer 74, 1292-1296 (1996).
69. Miles D, Ibrahim N, Roche U et al. An international, randomized Phase III clinical trial of STn-KLH (Theratope) therapeutic cancer vaccine in metastatic breast cancer patients. Breast Cancer Res. Treat. 82, 36 (2003).
70. Ibrahim, N, Murray, J. Clinical development of the STn-KLH vaccine (Theratope®). Clin. Breast Cancer 3(Suppl. 4), S139-S143 (2003).
71. Ibrahim N, Murray J, Parker J, Finke L, Miles D. Humoral immune responses to naturally occurring STn in metastatic breast cancer patients (MBC pts) treated with STn-KLH vaccine. Proc. Am. Soc. Clin. Oncol. 23, 174 (2004).
72. Mayordomo J, Tres A, Miles D, Finke L, Jenkins H. Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in stage IV breast cancer following first chemotherapy. Proc. Am. Soc. Clin. Oncol. 23, 188 (2004).
73. Svane I, Pedersen A, Johnson HE et al. Vaccination with p53 peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a Phase I study. Cancer Immunol. Immunother. 53, 633-641 (2004).
74. Ahlert T, Sauerbrei W, Bastert G et al. Tumor cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer. J. Clin. Oncol. 15, 1354-1366 (1997).
75. Wiseman C. Inflammatory breast cancer: 10-year follow-up trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy. Cancer Invest. 13, 267-271 (1995).
76. Dols A, Meijer S, Hu H-M et al. Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J. Immunother. 26, 163-170 (2003).
77. Dols A, Smith J II, Meijer S et al. Vaccination of women with metastatic breast cancer using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic breast cancer cell line: clinical and immunological results. Human Gene Ther. 14, 1117-1123 (2003).
78. Avigan D, Vosir B, Gong T et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10, 4699-4708 (2004).
79. Emens L, Machiels J, Reilly R, Jaffee E. Chemotherapy: friend or foe to cancer vaccines? Curr. Opin. Mol. Ther. 3, 77-82 (2001).
80. Klapper L, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 60, 3384-3348 (2000).
81. Castilleja A, Ward N, O'Brian C et al. Accelerated HER-2 degradation enhances ovarian tumor recognition by CTL. Implications for tumor immunogenicity. Mol. Cell Biochem. 217, 21-33 (2001).
82. Gabrilovich D, Ishida T, Nadaf S, Ohm J, Carbone D. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 5, 2963-2970 (1999). First published report demonstrating the ability of vascular endothelial growth factor blockade to augment immune function.
83. Phan G, Yang J, Sherry R et al. Cancer regression and autoimmunity induced by cytotoxic T-lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. 100, 8372-8377 (2003). One of first two published reports of cytotoxic T-lymphocyte antigen (CTLA)-4 blockade in humans.
84. Attia P, Phan G, Maker A et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23, 1-11 (2005).
85. Sanderson K, Scotland R, Lee P et al. Autoimmunity in a Phase I trial of a fully human anticytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected Stages III and IV melanoma. J. Clin. Oncol. 23, 741-750 (2005).
86. von Mehren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7, 1181-1191 (2001).
87. Jaffee E, Hruban R, Biedrzycki B et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a Phase I trial of safety and immune activation. J Clin. Oncol. 19, 145-156 (2001).
88. + T-cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J. Exp. Med. 200, 297-306 (2004).
89. Cho B, Rao V, Ge Q, Eisen H, Chen J. Homeostasis-stimulated proliferation drives naive T-cells to differentiate directly into memory T-cells. J. Exp. Med. 192, 549-556 (2000).
90. Goldrath A, Bogatzki L, Bevan M. Naive T-cells transiently aquire a memory-like phenotype during homeostasis-driven proliferation. J. Exp. Med. 192, 557-564 (2000).
91. Mackall C, Bare C, Granger L et al. Thymic-independent T-cell regeneration occurs via antigen-driven expansion of peripheral T-cells resulting in a repertoire that is limited in diversity and prone to skewing. J. Immunol. 156, 4609-4616 (1996).
92. Hu H-M, Poehlein C, Urba W, Fox B. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 62, 3914-3919 (2002).
93. Borrello I, Sotomayo E, Rattis FM et al. Sustaining the graft-versus-tumor effect through posttransplant immunization with granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing tumor vaccines. Blood 95, 3011-3019 (2000).
94. Teshima T, Mach N, Hill G et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res. 61, 162-171 (2001).
95. + regulatory T-cells suppress tumor immunity but are sensitive to cyclophosphamide, which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34, 336-344 (2004).
96. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105, 2862-2868 (2005).
97. Machiels JP, Reilly R, Emens L et al. Cyclophosphamide, doxorubicin, and paditaxel enhance the antitumor immune response of GM-CSF secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61, 3689-3697 (2001). First published report of chemotherapy-modulated vaccination for cancer in a characterized model of immune tolerance.
98. high T-lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95, 2024-2030 (2000).
99. Loeffler M, Kruger J, Reisfeld R. Immunostimulatory effects of low-dose cyclophosphamide are controlled by inducible nitric oxide synthase. Cancer Res. 65, 5027-5030 (2005).
100. Kawasaki K, Akashi S, Shimazu R et al. Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. J. Biol. Chem. 275, 2251-2254 (2000).
101. Bryd-Leifer C, Block E, Takeda K, Akira S, Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur. J. Immunol. 31, 2448-2457 (2001).
102. Wang J, Kobayashi M, Han M et al. MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-α expression in human myelomonocytic cells. Br. J. Hematol. 118, 638-645 (2002).
103. Demaria S, Volm M, Shapiro R et al. Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paditaxel chemotherapy. Clin Cancer Res. 7, 3025-3303 (2001).
104. Nigam A, Yacavone R, Zahurak M et al. Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines. Int. J. Cancer 12, 161-170 (1998). First published report of chemotherapy-modulated vaccination for cancer.
105. Eralp Y, Wang X, Wang J et al. Doxorubicin and paditaxel enhance the antitumor efficacy of vaccines directed against HER-2/neu in a murine mammary carcinoma model. Breast Cancer Res. 6, R275-R283 (2004).
106. Yu B, Kusmartsev S, Cheng F et al. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental cancer. Clin. Cancer Res. 9, 285-294 (2003).
107. Guy C, Webster M, Schaller M et al. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. 89, 10578-10582 (1992).
108. Reilly R, Gottlieb M, Ercolini A et al. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60, 3569-3576 (2000).
109. Ercolini A, Machiels J-P, Chen Y et al. Identification and characterization of the immunodominant rat HER-2/neu MHC Class I epitope presented by spontaneous mammary tumors from HER-2/neu transgenic mice. J. Immunol. 170, 4273-4280 (2003).
110. Emens L, Armstrong D, Biedrzycki B et al. A Phase I vaccine safety and chemotherapy dose-finding trial of an allogeneic GM-CSF-secreting breast cancer vaccine given in a specifically timed sequence with immunomodulatory doses of cyclophosphamide and doxorubicin. Human Gene Ther. 15, 313-337 (2004).
111. + T-cell effector function and tumor-free survival in HER-2/neu transgenic mice. J. Immunol. 15, 2161-2169 (2003). Demonstrates enhanced antigen-specific immune responses with combined monoclonal antibody and vaccine therapy.
112. Hurwitz A, Yu T, Leach D, Allison J. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. 18, 10067-10071 (1998).
113. van Elsas A, Hurwitz A, Allison J. Combination immunotherapy of B16 melanoma using anticytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
114. Hodi F, Mihm M, Soiffer R et al. Biologic activity of cytotoxic T-lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. 100, 4712-4717 (2003). One of first two published reports of CTLA-4 blockade in humans.
115. Sugamura K, Ishii N, Weinberg A. Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nature Rev. Immunol. 4, 420-431 (2004). A comprehensive review of OX40 biology.
116. Morris A, Vetto J, Ramstad R et al. Induction of antimammary cancer immunity by engaging OX-40 receptor in vivo. Breast Cancer Res. Treat 67, 71-80 (2001).
117. Pan P, Zang Y, Weber K, Meseck M, Chen S. OX40 ligation enhances primary and memory cytotoxic T-lymphocyte responses in an immunotherapy for hepatic colon metastases. Mol. Ther. 6, 528-536 (2002).
118. Gri G, Gallo E, Di Carlo E, Musiani P, Colombo M. OX40 ligand-transduced tumor cell vaccine synergizes with GM-CSF and requires CD40-APC signaling to boost the host T-cell antitumor response. J. Immunol. 170, 99-106 (2003).